Genenta Science S.p.A. (GNTA)

NasdaqCM - NasdaqCM Delayed price. Currency in USD

Add to watchlist

2.5900

-0.3400

(-11.60%)

At close: 04:00PM EDT

2.3500

-0.24

(-9.27%)

After hours:

05:02PM EDT

Trade prices are not sourced from all markets

All

GlobeNewswire
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors
Based on Preliminary Data from Ongoing Dose Ranging Stage of the Phase 1/2 Clinical TrialMILAN, Italy and NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that: We have successfully dosed the first of three patients in Cohort 8 (Temferon™ at 4x10^6/kg), the last cohort o
Simply Wall St.
Is Genenta Science (NASDAQ:GNTA) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St.
Individual investors account for 54% of Genenta Science S.p.A.'s (NASDAQ:GNTA) ownership, while insiders account for 30%
Key Insights Significant control over Genenta Science by individual investors implies that the general public has more...